Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
我们的管线数据、历史指标、交易和里程碑信息和预测全面满足您优化投资组合的数据需求。
As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.
How we can help
Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
In Vivo
By William Looney 14 Nov 2022
The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.
Datamonitor Healthcare
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
In Vivo
14 Nov 2022
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
In Vivo
By Jo Shorthouse 14 Nov 2022
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
Datamonitor Healthcare
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topic Cancer
Datamonitor Healthcare
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
In Vivo
02 Mar 2022
Look ahead with our Pharma Outlook 2022 Extract as we discuss what's coming up in the biopharma space.
In Vivo
By Alex Shimmings 05 Jan 2022
2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.
In Vivo
By Ashley Yeo 28 Dec 2021
At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.
In Vivo
By Lucie Ellis-Taitt 22 Nov 2021
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
Pharma Competitive Intelligence
18 Nov 2021
Scrip's team of trusted industry experts bring you the mos critical news and analysis on key commercial topics, from licensing to clinical trials, and competitor activity, around the clock. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.
In Vivo
By Joanne Shorthouse 17 Nov 2021
Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.
In Vivo
By Ben Comer 14 Oct 2021
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
In Vivo
08 Oct 2021
The highly anticipated Outlook 2022 report from Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.
Biomedtracker, Datamonitor Healthcare
22 Sep 2021
Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.
In Vivo
01 Jun 2023
In Vivo
31 May 2023
In Vivo
31 May 2023
In Vivo
25 May 2023
In Vivo
25 May 2023
In Vivo
24 May 2023
In Vivo
24 May 2023
In Vivo
22 May 2023
In Vivo
22 May 2023
In Vivo
22 May 2023
In Vivo
17 May 2023
In Vivo
17 May 2023
In Vivo
16 May 2023
In Vivo
15 May 2023
In Vivo
15 May 2023
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
报告商城
迫切需要某一领域的的全面信息？
不妨在我们的报告商城中搜索是否有符合您需求的相关报告—— 海量实用报告供您甄选。
